Ponatinib is a drug of several generations

Ponatinib (Ponatinib) is a type of drug called a tyrosine kinase inhibitor (TKI), a class of drugs used to treat certain types of cancer, particularly chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Ponatinib is a third-generation dual Src-ABL inhibitor with activity against BCR-ABL forms that harbor mutations that confer resistance to other TKIs, specifically the T315I mutation.

Ponatinib binds to ABL in the inactive form of imatinibInitial cell- and mouse-based studies showed that ponatinib inhibits cells expressing mutant or native BCR-ABL. Subsequent studies have shown that ponatinib is active against chronic myelogenous leukemia (CML), including CML with the T315I mutation. Toxicity observed in early clinical trials included pancreatitis and elevated pancreatic enzymes, fatigue, rash, and elevated aminotransferase levels. Ponatinib received accelerated approval from the FDA in 2012 for the treatment of drug-resistant or intolerant CML and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

The original drug of Ponatinib has not yet been launched in China, so it is not included in the medical insurance. Domestic patients in need may only purchase it through overseas channels. The Hong Kong original version of Ponatinib specificationsThe price of 45mg*30 tablets per box may be around 40,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There are also generic ponatinib drugs produced in other countries, which are relatively cheap. The price of 45mg*30 tablets per box produced by Everest Pharmaceutical Factory in Bangladesh may be around 4,000 yuan (the price may fluctuate due to the exchange rate), and its drug ingredients are basically the same as those of the original drug.